Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, M.D., Deborah Thomas, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, John T Manning, MD, L. Jeffrey Medeiros, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Aziz Nazha, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Stefan Faderl, MD

Blood (2012) 120 (21): 3554.

https://doi.org/10.1182/blood.V120.21.3554.3554

Published: 2012

Journal Articles

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Cecilia Y Arana Yi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD, Ph.D., Gautam Borthakur, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Sherry A. Pierce, RN, BS, Michael Andreeff, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3557.

https://doi.org/10.1182/blood.V120.21.3557.3557

Published: 2012

Journal Articles

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Megan Othus, PhD, Hagop M. Kantarjian, MD, Stephen Petersdorf, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Sherry A. Pierce, RN, BS, Harry Paul Erba, MD, PhD, Stefan Faderl, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 129.

https://doi.org/10.1182/blood.V120.21.129.129

Published: 2012

Journal Articles

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Christopher B. Benton, MD, Peng Qiu, PhD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, RN, BS, Anisha Borthakur, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Michael Andreeff, MD, PhD, Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1417.

https://doi.org/10.1182/blood.V120.21.1417.1417

Published: 2012

Journal Articles

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Maro Ohanian, DO, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Alfonso Quintas-Cardamas, MD, Elias Jabbour, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Stefan Faderl, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1456.

https://doi.org/10.1182/blood.V120.21.1456.1456

Published: 2012

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs).

Naveen Pemmaraju, M.D., Hagop M Kantarjian, M.D., Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD, Sherry A. Pierce, RN, BS, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 2845.

https://doi.org/10.1182/blood.V120.21.2845.2845

Published: 2012

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 1693.

https://doi.org/10.1182/blood.V120.21.1693.1693

Published: 2012

Journal Articles

Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS)

Yue Wei, PhD, Rui Chen, Sophie Dimicoli, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Donna S. Neuberg, ScD, Sherry A. Pierce, RN, BS, Hui Yang, MD, PhD., Yu Jia, Hong Zheng, Zhihong Fang, Martin Nguyen, Michael Fernandez, Sa A. Wang, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 1700.

https://doi.org/10.1182/blood.V120.21.1700.1700

Published: 2012

Journal Articles

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, Lakshmikanth Katragadda, MD, Gabriela Rondon, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2001.

https://doi.org/10.1182/blood.V120.21.2001.2001

Published: 2012

Journal Articles

A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC

Francesco Paolo Tambaro, MD, PhD, Guillermo Garcia-Manero, MD, Wei Qiao, Sherry A. Pierce, RN, BS, Mimmo Ripaldi, MD, Stefan Faderl, MD, Hagop M Kantarjian, William G. Wierda, MD, PhD, Jorge E Cortes, MD

Blood (2012) 120 (21): 131.

https://doi.org/10.1182/blood.V120.21.131.131

Published: 2012

Journal Articles

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Betul Oran, MD, MS, Farhad Ravandi, MD, Hady Ghanem, MD, Issa Khouri, MD, Guillermo Garcia-Manero, MD, Michael S Mathisen, PharmD, Qaiser Bashir, MD, Rima M Saliba, PhD, Maria Khouri, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Richard E. Champlin, Marcos De Lima, MD

Blood (2012) 120 (21): 2029.

https://doi.org/10.1182/blood.V120.21.2029.2029

Published: 2012

Journal Articles

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Koichi Takahashi, MD, Naveen Pemmaraju, M.D., Miloslav Beran, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Elias J. Jabbour, MD, Naval Daver, MD, Zeev Estrov, MD, PhD, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3797.

https://doi.org/10.1182/blood.V120.21.3797.3797

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

Journal Articles

Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients

Hui Yang, MD, PhD., Carlos E. Bueso-Ramos, MD, PhD, Sherry A. Pierce, RN, BS, Yue Wei, PhD, Zhihong Fang, Martin Nguyen, Michael Fernadez, Marylou Cardenas-Turanzas, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3845.

https://doi.org/10.1182/blood.V120.21.3845.3845

Published: 2012

Journal Articles

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Koichi Takahashi, MD, Elias J. Jabbour, MD, Xuemei Wang, MS, Hady Ghanem, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3802.

https://doi.org/10.1182/blood.V120.21.3802.3802

Published: 2012

Journal Articles

Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Guillermo Garcia Manero, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Koichi Takahashi, MD, Susan M. O'Brien, MD, Sherry A. Pierce, RN, BS, Tapan M. Kadia, M.D., Elias J. Jabbour, MD

Blood (2012) 120 (21): 3600.

https://doi.org/10.1182/blood.V120.21.3600.3600

Published: 2012

Journal Articles

Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas

Hui Yang, MD, PhD., Carlos E. Bueso-Ramos, MD, PhD, Simrit Parmar, M.D., Yue Wei, PhD, Zhihong Fang, Martin Nguyen, Michael Fernandez, Sherry A. Pierce, RN, BS, Qirong Geng, Hagop M. Kantarjian, MD, Jorge E Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3810.

https://doi.org/10.1182/blood.V120.21.3810.3810

Published: 2012

Journal Articles

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Steven M. Kornblau, MD, PhD, Stefan Faderl, MD, Alessandra Ferrajoli, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3774.

https://doi.org/10.1182/blood.V120.21.3774.3774

Published: 2012

NARROW

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs).

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS)

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure

Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only